Last reviewed · How we verify

PemCarbo — Competitive Intelligence Brief

PemCarbo (PemCarbo) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination (antifolate + platinum agent). Area: Oncology.

phase 3 Chemotherapy combination (antifolate + platinum agent) Thymidylate synthase, dihydrofolate reductase (pemetrexed); DNA (carboplatin) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

PemCarbo (PemCarbo) — Asan Medical Center. PemCarbo is a combination chemotherapy regimen pairing pemetrexed (an antifolate antimetabolite) with carboplatin (a platinum-based alkylating agent) to inhibit DNA synthesis and repair.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
PemCarbo TARGET PemCarbo Asan Medical Center phase 3 Chemotherapy combination (antifolate + platinum agent) Thymidylate synthase, dihydrofolate reductase (pemetrexed); DNA (carboplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination (antifolate + platinum agent) class)

  1. Asan Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PemCarbo — Competitive Intelligence Brief. https://druglandscape.com/ci/pemcarbo. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: